- Shares of Opko have declined around 20% in the last 3 months due to Jefferies negative commentary
- We believe Rayaldy and 4Kscore have a billion dollar market potential
- The company will be able to recover lost value on major approaching catalysts
In the last 3 months shares of Opko Health (OPK) have declined around 20%. The primary reason behind this decline was some negative commentary by Jefferies. However, in the last couple of months the valuations have stabilized around the $8 mark. We believe that Opko is one of the safer and more rewarding investments out there and is a buy at the current price levels. Our analysis also shows that 4Kscore and Rayaldy have a huge market potential and can turn out to be billion dollar products.
OPKO Is a multinational company involved in the discovery and development of next generation therapies and